The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation by Hiippala, Kaisa et al.
nutrients
Review
The Potential of Gut Commensals in Reinforcing
Intestinal Barrier Function and
Alleviating Inflammation
Kaisa Hiippala 1, Hanne Jouhten 1, Aki Ronkainen 1, Anna Hartikainen 1, Veera Kainulainen 2,
Jonna Jalanka 1 and Reetta Satokari 1,* ID
1 Immunobiology Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland;
kaisa.hiippala@helsinki.fi (K.H.); hanne.jouhten@helsinki.fi (H.J.); aki.ronkainen@helsinki.fi (A.R.);
anna.hartikainen@helsinki.fi (A.H.); jonna.jalanka@helsinki.fi (J.J.)
2 Pharmacology, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland;
veera.kainulainen@helsinki.fi
* Correspondence: reetta.satokari@helsinki.fi; Tel.: +358-504-489-368
Received: 1 July 2018; Accepted: 27 July 2018; Published: 29 July 2018


Abstract: The intestinal microbiota, composed of pro- and anti-inflammatory microbes, has an essential
role in maintaining gut homeostasis and functionality. An overly hygienic lifestyle, consumption of
processed and fiber-poor foods, or antibiotics are major factors modulating the microbiota and possibly
leading to longstanding dysbiosis. Dysbiotic microbiota is characterized to have altered composition,
reduced diversity and stability, as well as increased levels of lipopolysaccharide-containing,
proinflammatory bacteria. Specific commensal species as novel probiotics, so-called next-generation
probiotics, could restore the intestinal health by means of attenuating inflammation and strengthening
the epithelial barrier. In this review we summarize the latest findings considering the beneficial
effects of the promising commensals across all major intestinal phyla. These include the already
well-known bifidobacteria, which use extracellular structures or secreted substances to promote
intestinal health. Faecalibacterium prausnitzii, Roseburia intestinalis, and Eubacterium hallii metabolize
dietary fibers as major short-chain fatty acid producers providing energy sources for enterocytes
and achieving anti-inflammatory effects in the gut. Akkermansia muciniphila exerts beneficial action
in metabolic diseases and fortifies the barrier function. The health-promoting effects of Bacteroides
species are relatively recently discovered with the findings of excreted immunomodulatory molecules.
These promising, unconventional probiotics could be a part of biotherapeutic strategies in the future.
Keywords: commensal bacteria; intestinal health; next generation probiotics; dysbiosis; intestinal
permeability; butyrate producing bacteria; anti-inflammatory
1. Introduction
The human gastrointestinal microbiota is a complex ecosystem consisting mainly of bacteria,
but also viruses and eukaryotic organisms. It has been estimated that we harbor 1013 bacterial cells,
which equals the number of eukaryotic cells in the human body [1]. In total, over 3000 bacterial species
have been found in human feces to date [2], although only 1000 of these have been characterized by
culturing, while the remaining have only been detected by sequencing [3]. Most individuals have
around 200 different species in their digestive tract with highly variable abundance and a combination
that makes the microbiota make-up very personal [4]. From this bacterial population about 30% are
shared between subjects, creating the so-called common core microbiota [4,5].
The intestinal microbiota affects the human health in many ways and is considered a major
contributing factor in a number of diseases. Microbiota plays a role in the maintenance of the intestinal
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barrier, which is essential for homeostasis and functionality of the gut. Impaired barrier function
is associated with both intestinal and systemic diseases. In a balanced situation regarding the pro-
and anti-inflammatory properties of the microbiota, it stimulates and challenges the host and its
immune system at an appropriate level to keep the defense mechanisms alerted, while, at the same
time, providing regulatory signals to induce tolerance towards commensal microbiota.
The digestive tract has two distinct microbial ecosystems, the luminal and the mucosal
microbiota [6]. In the luminal compartment, over 90% of bacteria belong to Firmicutes and Bacteroidetes,
and the minor phyla include Actinobacteria, Proteobacteria, and Verrucomicrobia. In the mucosal
layer, the number of bacteria, as well as the diversity, is considerably lower, and the composition is
clearly different as Firmicutes are generally higher in abundance compared to the Bacteroidetes in both
humans [7] and mice [8].
Microbial composition is affected by a number of endogenous and exogenous factors, such as
hosts’ physiology and immunity, diet, and medication. In contemporary societies, an overly hygienic
lifestyle with few exposures to environmental microbes, consumption of processed and fiber-poor
foods and frequent use antibiotics are considered as major modulators of human microbiota [9]. Strong
perturbations like these may lead to a state of dysbiosis, which has been associated with a number of
human diseases [10]. The causal links between microbiota dysbiosis and disease states are currently
under intense investigation, as well as the mechanisms by which the microbiota could contribute to
the pathological processes [10].
Microbiota dysbiosis is generally characterized by altered composition, as well as reduced
diversity and stability [11]. This has also led to observations where the relative proportion of facultative
anaerobic bacteria has been increased and the proportion of strictly anaerobic bacteria with protective
functions, such as the production of short-chain fatty acids (SCFA) has been reduced [12]. Overall,
a dysbiotic microbiota has not only lost the capacity to support intestinal homeostasis, but it may
even exacerbate intestinal inflammation [11]. For example, an increase in the gamma-Proteobacteria
levels with highly proinflammatory cell wall structures, i.e., lipopolysaccharide (LPS), will induce
inflammation and the following oxidative stress, in turn, will exacerbate dysbiosis by promoting
facultative anaerobic bacteria [13]. Furthermore, microbiota dysbiosis can impair the epithelial barrier
leading to so-called leaky gut allowing the intestinal content to be in contact with the host periphery
potentially inducing inflammatory responses, which is often observed in several human diseases [12].
While anti-inflammatory drugs provide different alternatives to dampen inflammation effectively,
it would also be essential to treat the microbial dysbiosis and strengthen the epithelial integrity in order
to restore intestinal homeostasis in the long-term. The growing knowledge of the importance of the
human microbiota suggests that commensal species can be isolated and used for therapeutic purposes
as so-called next-generation probiotics, alongside lactobacilli and bifidobacteria with a long history
of use as probiotics. Next-generation probiotics are potential novel health-promoting commensal
strains, which have not yet been used for nutritional and therapeutic purposes and could possibly be
exploited in dietary and pharmaceutical applications. Emerging evidence shows that a large number
of commensal species across all major intestinal phyla have the ability to strengthen the epithelial
barrier and alleviate inflammation, as will be discussed in the following sections.
In this review we summarize the beneficial effects of well-known, promising commensal
bacteria on the intestinal epithelial barrier and discuss their possible use as unconventional, so-called
next-generation probiotics of the future. The importance of butyrate-producing bacteria to the intestinal
health is well documented, but at the molecular level the mechanisms, e.g., effector molecules secreted
by commensal bacteria, are still being investigated. Hence, this review summarizes the potential
mechanisms known so far behind the health-promoting action of the commensals in the gut.
2. Intestinal Barrier Function
The intestinal epithelium acts as a barrier between the host and the luminal confinement of
commensal bacteria, enabling the symbiotic relationship between the two (Figure 1). In addition to
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the physical barrier of epithelial cells and mucus layer, other host defense mechanisms include the
secretion of antimicrobial peptides (AMPs) and secretory immunoglobulin A (sIgA), as well as the
presence of immune cells like phagocytes and macrophages [14]. The most prominent antimicrobial
peptides include defensins, cathelicidins, and C-type lectins, which are expressed as a result of pattern
recognition receptor (PRR) activation in the intestinal epithelial cells [15]. In order to sustain intestinal
integrity, the epithelial cells need to be renewed constantly by continuous differentiation from stem cells
to goblet cells, Paneth cells, enteroendocrine cells, or enterocytes [16]. Enterocytes form the physical
barrier by linking together with different cell junctions, including desmosomes, adherens junctions,
and tight junctions. In turn, goblet cells secrete mucin, which forms a thick, protective mucus layer on
the epithelial mucosa. Paneth cells are specialized producers of antimicrobial molecules mostly located
in the small intestine. Endocrine cells secrete serotonin and various neuropeptides, which act as signals
in the crosstalk between the enteroendocrine cells and the immune system. Gut-associated lymphoid
tissue (GALT) is located under the epithelial layer, where submucosal dendritic cells (DCs) sample
antigens from the lumen or luminal antigens are presented to DCs by microfold cells (M-cells) leading to
the activation of IgA secretion [17]. Recently it was discovered that IgA, besides its defensive role, also
generates host–microbe symbiosis by enabling mucosal colonization of bacteria [18]. Bacteroides fragilis
modulates its surface structures to bind IgA, which is needed for the colonization of the mucosal niche
in the gut.
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Tight junctions, such as claudins and occludin, are intercellular junctions connecting the epithelial
cells tightly together and controlling the paracellular permeability [19]. Hence, the tight junction
proteins also moderate the transepithelial transport. The intestinal barrier enhancement, for example,
by probiotic bacteria, is associated with changes in the tight junction protein expression and distribution.
Intestinal inflammation, commensal microbes, and dietary components are among the main factors
affecting epithelial permeability [20]. Food factors, including amino acids like glutamine and
tryptophan, as well as polyphenols, enhance the barrier integrity. Glutamine, a well-studied food
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component, is a primary energy source for enterocytes, which regulates tight junction expression and
localization in Caco-2 intestinal cells [21]. On the other hand, there are also detrimental food factors,
such as dietary saturated fat, which has been shown to increase intestinal permeability in vivo [22].
In general, more studies on the effect of nutrition on intestinal barrier function and the mechanisms
are needed.
3. Proteobacteria as a Marker of Dysbiosis and Mediator of Inflammation
In a healthy intestine, Proteobacteria is numerically a minor phyla. Increased abundance
of Proteobacteria, particularly the class gamma-Proteobacteria and the family Enterobacteriaceae
within it, has been associated with a number of human diseases [23]. As Gram-negative bacteria
their outer membrane surface is covered with LPS, which is a complex glycolipid and a major
bacterial virulence factor [24,25]. The LPS molecule is composed of three domains; lipid A, core,
and O-specific polysaccharides [26]. The lipid A structure, which determines the immunogenicity
of LPS, differs among different bacterial species. Most of the Gram-negative bacteria express the
hexaacylated LPS, which is one of the most potent agonists of the human innate immune system. LPS
triggers a strong proinflammatory reaction and secretion of proinflammatory cytokines from the host
cells [27]. Proinflammatory cytokines include interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α),
and interleukin-1β (IL-1β), whereas anti-inflammatory cytokines IL-10 and IL-17 decrease and restore
the intestinal permeability [20]. In addition of hexaacylation, tetraacylated and pentaacylated LPS
also exist among Gram-negative bacteria. The number of lipid A acyl chains usually correlates well
with its ability to induce proinflammatory cytokine production and the hexaacylated forms are the
most proinflammatory ones [28]. Consequently, proinflammatory cytokines involved in the intestinal
inflammation modify the tight junctions leading to disruption of the intestinal barrier, which plays
a role in the pathogenesis of many intestinal diseases, such as inflammatory bowel disease (IBD).
Due to the highly proinflammatory cell wall structure, Proteobacteria can induce and maintain
unspecific inflammation in the intestine without an actual infection if their abundance in the gut
microbiota has been increased. The Proteobacteria phylum also includes several notable human
pathogens. The high abundance of Proteobacteria has been associated with many disease conditions
where intestinal or systemic inflammation or both of these are involved as a key pathoetiological factors.
For example, the connection between LPS sustained low-grade inflammation and the development
of metabolic disorders has been well established [29]. It has been shown that members of the
Enterobacteriaceae family are more abundant in obese people when compared to healthy controls with
normal weight. After weight loss, the Enterobacteriaceae population was the most affected family
with the relative abundance decreasing from 13% to less than 1% [30]. Furthermore, it was shown
that gamma-Proteobacteria were increased in the intestines of patients suffering from nonalcoholic
fatty liver disease and nonalcoholic steatohepatitis (NASH) [31]. When comparing the microbiota
composition of healthy and obese children, as well as children suffering from NASH, a gradual increase
in Proteobacteria has been observed, respectively [32]. Proteobacteria have also been found to be
increased in the microbiotas of IBD patients [33–35].
Despite the proinflammatory nature of Proteobacteria, it has been well established that there are
strain-dependent variations in the immunomodulatory properties. A striking example of this is the
Proteobacteria Escherichia coli Nissle 1917 (EcN), which is widely used as a probiotic strain [36]. EcN
has a specific LPS form, due to a point mutation, which gives it an ability to withstand antibacterial
defense mechanisms of blood serum [37]. EcN has been shown to have efficacy in reducing the severity
of rotaviral diarrhea and modulating viral immunity in several randomized clinical studies and
experimental studies in an animal models [38–43]. In addition, it has been shown to very efficiently
maintain remission in ulcerative colitis (UC) [44–46]. Interestingly, the probiotic effect of EcN is,
in part, due to its antimicrobial effect via the production of bacteriocins and inhibition of other
E. coli strains [47]. Furthermore, EcN interacts with the gut epithelium by inducing the defensin
production, strengthening the epithelial layer, decreasing the production of proinflammatory cytokines,
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and increasing the production of anti-inflammatory cytokines [47]. Thus, EcN seems to counteract the
proinflammatory effects commonly induced by Proteobacteria.
4. Health-Associated Commensal Bacteria
A dysbiotic microbiota can be ameliorated with the health-promoting action of next-generation
probiotics or boosting the growth and metabolism of beneficial commensals in the colon with fiber-rich
food components, especially targeting the butyrate production. The protective effect of commensal
bacteria on barrier function is achieved by preventing the colonization of pathogens, interacting
directly with the host enterocytes and metabolizing undigested carbohydrates to short-chain fatty
acids (Figure 1). Commensal bacteria metabolize dietary fibers and resistant starch to SFCAs, such
as butyrate, acetate, and propionate, which serve as a major energy source for the host enterocytes
(Figure 2). Dietary fibers and SFCAs have been shown in vivo to suppress intestinal inflammation and
colon cancer [48]. Microbial-derived butyrate increases mitochondrial-dependent oxygen consumption
in enterocytes, stabilizes the hypoxia-inducible factor (HIF) involved in barrier protection, and induces
expression of HIF-target genes that augment barrier function [49]. On the other hand, intestinal
homeostasis is also maintained via direct interaction of the microbiota and the host epithelium and
immune system, where the recognition of bacterial molecules, such as LPS, by host PRRs plays a major
role (Figure 1) [50].
In the following paragraphs, we summarize the recent research results from the promising,
cultivable commensal bacteria with health-promoting and anti-inflammatory capacity in the gut.
Probiotic characteristics are generally considered strain-dependent and, therefore, cannot be
generalized to cover other than the studied strain of the species unless the mechanism of action is
known and the strains in question are known to harbor or produce the effector molecules [51,52]. There
is a strong evidence of strain-specificity, as well as disease-specificity of probiotic action, which makes
it very challenging to authenticate the efficacy of probiotics in clinical trials [52]. Furthermore, it can
be difficult to show the beneficial action of probiotics in healthy individuals by recording specific
biomarkers rather than symptoms and if the study cohort is not a high-risk population with elevated
levels of biomarkers [53]. Thus, all strains of a specific species cannot be expected to exert all described
traits described below, but the purpose is rather to give an overview of the beneficial traits found
within a species or genus.
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4.1. Bifidobacterium spp.
The genus Bifidobacterium, belonging to the phylum Actinobacteria, contains 51 recognized species
and 10 subspecies [56], the majority of which originate from human or animal (mammals and bees)
digestive tracts, and also few species that have been originally isolated from other sources, such
as milk or sewage [57]. For 100 years these bacteria have been considered health-promoting and
bifidobacterial strains have been widely used as probiotics along with lactobacilli. The level of
knowledge concerning the health-promoting mechanisms of action, as well as the efficacy of bacteria
marketed as probiotics varies substantially between strains, which can complicate the comparison
and selection of certain strains to specific indications [58]. However, some strains of Lactobacillus and
Bifidobacterium spp. are extensively characterized, also in comparative genomics studies, which makes
them good examples and forerunners in the search of next-generation probiotics targeted for specific
therapeutic purposes [57,59].
In humans, bifidobacteria are among the founder-species of the infant gut and frequently one of
the major taxa or even the most abundant genus of infant gut microbiota [60]. In vaginally born infants,
bifidobacteria are found within three days after birth, and after one week they may compose as high
as 96.4% of the overall microbiota in breast-fed infants [61,62]. Bifidobacteria seem to be transferred
vertically from mother to infant as evidenced by both metagenomic studies and whole genome
sequencing of isolated strains from mother-infant pairs [61,63,64]. Duranti et al. [61] showed that strains
of B. longum, B. bifidum, B. breve, B. adolescentis, B. dentium, B. pseudocatenulatum, and B. catenulatum,
i.e., representatives of all major human bifidobacterial species, were shared between the mothers and
their infants. The relative proportion of bifidobacteria in children declines after weaning, but stays
higher than in adults over the childhood and pre-adolescentis years [65,66]. The abundance of
bifidobacteria in adults is estimated to be 1–2% in many countries around the world, and approximately
7% in the Japanese population [66]. The age-related decline in the proportion of bifidobacteria seem to
continue until senescence.
Human milk oligosaccharides (HMOs) stimulate the growth of bifidobacteria, but different
species and strains have their specific HMO preferences [67]. For example a positive correlation
was found between sialylated HMOs and B. breve and non-fucosylated/non-sialylated HMOs and
the B. longum group [67]. Likewise, bifidobacterial species and subspecies have different abilities
to degrade glycans of the intestinal mucus layer and plant-derived polysaccharides, which makes
some strains better adapted to infant gut, while some are better adapted to adults [68–70]. On the
other hand, B. breve has capabilities to utilize both plant- and host-derived carbohydrates and could,
therefore, be called a generalist [71]. Altogether, bifidobacterial genomes are better equipped with
genes related to carbohydrate metabolism than average bacterial genomes, and by resource sharing and
cross-feeding, bifidobacteria may have large effects on overall gut physiology [71]. In vitro co-culture
studies have shown that bifidobacteria have the ability to degrade oligo-fructose and produce
acetate, thereby promoting butyrate production of Faecalibacterium prausnitzii, Anaerostipes caccae,
and Roseburia intestinalis, by means of cross-feeding [72–74]. Detailed knowledge on the metabolic
capabilities and cross-feeding chains could open a possibility to modulate the composition and action
of gut microbiota in a desired direction by premeditated dietary fiber consumption.
Epithelial adhesion of bifidobacteria is mediated by extracellular structures, e.g., pili or fimbriae
and the extracellular polysaccharide (EPS) layer or capsule (Table 1) [57]. Most strains of bifidobacteria
have pilus-encoding loci in their genomes. The role of pili in mediating bifidobacterial adhesion to
enterocytes, as well as in autoaggregation, was first demonstrated for B. bifidum [75]. In a murine
model, B. bifidum pili evoked TNF-α expression and a significantly lower IL-10 response in cecal
mucosa as compared to nonpiliated cells [75]. Later, another type of pili, tight adherence (Tad) pili
were discovered in B. breve [76]. Interestingly, the genes of B. breve Tad-pilus were found to be heavily
up-regulated in vivo in a mouse model as compared to in vitro cultivation [76]. Experiments with
pilusless mutant strains confirmed the importance of this structure in the colonization and persistence
of B. breve in the gut. In addition to pili, other surface structures of bifidobacteria such as EPS,
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also have interesting functional properties. EPS provides acid and bile resistance to bacteria and
can act as an immunological silencer by modulating B-cell trafficking and IL-12 production in the
epithelium [77]. Furthermore, EPS may play a role in reducing initial colonization and burden of
pathogens as evidenced by Citrobacter rodentium infection mouse model [77].
In addition to extracellular structures, also secreted substances of bifidobacteria can mediate
probiotic effects. Acetate, an end product of bifidobacterial fermentation, can give protection against
E. coli O157 by affecting the regulation of certain genes involved in anti-inflammatory responses and
preventing or alleviating damage to intestinal epithelium due to E. coli O157-induced cell death and
reducing the translocation of toxins from gut to systemic circulation [78]. The resistance to infection
was mediated through a higher amount of mouse fecal acetate produced by certain bifidobacterial
strains, while the growth rate or the expression of virulence genes of E. coli O157 were not affected.
The role of acetate was apparent also in the ability of a B. bifidum strain to strengthen tight junctions and
prevent the disruption of epithelial barrier induced by TNF-α in vitro [79]. Antagonism of cytotoxic
effects of Clostridium difficile toxins by certain strains of bifidobacteria has been demonstrated with
HT29 intestinal epithelial monolayer, where effective strains were able to remove toxins from the
medium and preserve the F-actin microstructure and tight junctions between epithelium [80].
Recently, the immunomodulatory ability of various bifidobacterial species was studied with naïve
mouse spleen and dendritic cells and immunostimulatory patterns were found to be strain-specific
(Table 1) [81]. Interestingly, a strain with a low stimulatory potential in vitro was able to prevent
clinical symptoms in a mouse model of dextran sulfate sodium (DSS)-induced colitis, preserve the
tight junction protein expression, and protect the epithelial barrier function, while another strain of
the same species and with a higher in vitro immunomodulation capacity was not. These examples of
bifidobacterial ability to protect the epithelial barrier and interact with the host immunology tells about
strain-specific properties and highlights the need of a detailed characterization of selected bacteria and
their effects on the molecular level in the search for specific therapeutic properties of the bacteria.
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Table 1. Known effector molecules of the selected commensal bacteria and their effect on intestinal health. All in vivo studies were mice studies.
Organism Effector Molecule Mediated Effect Study Type Reference
B. breve UCC2003 IVb tight adherence (Tad) pili Host colonization and persistencemechanism in silico, in vivo [76]
B. breve UCC2003 Surface exopolysaccharide (EPS)
Acid and bile tolerance, immunomodulation,
protection against pathogen colonization
and burden
in silico, in vitro,
in vivo [77]
Several bifidobacterial strains Sortase-dependent pili Adhesion to host mucus components in silico, in vitro,in vivo [82]
B. bifidum PRL2010 Sortase-dependent pili Autoaggregation, evoked TNF-α expressionand a significantly lower IL-10 response in vitro, in vivo [75]
B. longum ssp. longum CCM 7952 Ligands for NOD2
Reduced clinical symptoms in a colitis
mouse model, preserved expression of tight
junction proteins
in vitro, in vivo [81]
A. muciniphila MucT Amuc_1100 (OM pili-like protein) Induction of cytokine production,interactionwith TLR 2, improves gut barrier in vitro [83,84]
A. muciniphila ATCC BA-835 Extracellular vesicles Improves intestinal barrier integrity,improved body weight & glucose tolerance in vitro, in vivo [85]
F. prausnitzii A2-165 Microbial anti-inflammatorymolecule (MAM)
Peptides of MAM inhibit the activation of
NF-κB, ameliorate colitis symptoms in mice in vitro, in vivo [86]
R. intestinalis DSMZ-14610 Flagellin Upregulation of IncRNA, alleviation ofcolonic inflammation in vitro, in vivo [87]
B. fragilis NCTC 9343 Polysaccharide A
Immune activation, elicits cytokine
production, protects and treats colitis in an
animal model
in vitro, in vivo [88]
B. fragilis 323-J-86 Outer-membrane vesicle Transports PSA molecule to immune cells in vitro, in vivo [89]
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Due to the high proportion of bifidobacteria in the healthy infant gut and the significant reduction
of it in the elderly, benefits of bifidobacterial probiotic strains, especially in those two age groups,
has raised interest. The effects of probiotic bifidobacteria on the health of pre-term infants is widely
studied and several systematic reviews and meta-analyses have found them effective in reducing the
risk of necrotizing enterocolitis and sepsis, which are major causes of death among pre-term infants,
and in reducing mortality and hospital stays [90–92]. In the elderly, bifidobacterial probiotics can
improve constipation and enhance cellular immune activity [93,94].
4.2. Akkermansia muciniphila
Akkermansia muciniphila is a Gram-negative, anaerobic, mucin-degrading bacterium which
belongs to the Planctomycetes-Verrucomicrobia-Chlamydia superphylum [95,96]. The type strain
A. muciniphila MucT was originally isolated from a healthy adult by using gastric mucin as a sole
carbon and nitrogen source [95,97]. Later, it was also found to tolerate low levels of oxygen [95,97].
By degrading the complex mucin glycoproteins and due to its ability to produce acetate, propionate
and 1,2-propandiol, A. muciniphila contributes to the bacterial community cross-feeding [95,98].
Co-culturing of butyrate-producing bacteria with A. muciniphila revealed two types of trophic chains,
metabolic and cofactor syntrophic interactions. [98]. First, A. muciniphila can metabolically support
the growth of butyrate-producers by degrading mucin and providing acetate. Second, A. muciniphila
can use pseudovitamin B12 produced by other bacteria for its propionate production. Additionally,
A. muciniphila produces sulfatases and it may be able to use hydrogen sulfide for cysteine production
and, as a result, limit the possible toxicity of sulfate-reducing bacteria [83,96].
The abundance of A. muciniphila has been found to be reduced in many disease states [99–103].
Studies on metabolic disorders, such as obesity and diabetes, have given the most promising evidence
on the beneficial effect of A. muciniphila on health [96]. Everard et al. [104] noticed that a daily
treatment with live A. muciniphila restored the mucus layer thickness in mice on a high-fat diet
(HF diet) and reversed the HF diet-induced metabolic disorders. The bacterium also contributed to the
production of antimicrobial peptides in the colon as it was found to affect RegIIIγ production [104].
Furthermore, administration of A. muciniphila increased the number of mucin-producing goblet
cells and anti-inflammatory regulatory T cells (Treg) in mice fed with HF-diet [105]. More recently,
the bacterium was shown to protect against atherosclerosis in an Apoe−/− mouse model by
attenuating metabolic endotoxemia-induced inflammation through restoration of the gut barrier [106].
In vitro results showing that A. muciniphila adheres to intestinal epithelial cell lines and strengthens
the cell monolayer support the idea that the bacterium has a special barrier fortifying function in the
epithelium [107]. A. muciniphila also induces only a low-level proinflammatory stimulation (IL-8) in
enterocytes as compared to E. coli, which may be beneficial to the gut health as it keeps the immune
system alerted [107]. Extracellular vesicles of A. muciniphila were also found to have a positive effect
on intestinal integrity, and due to their small size they may also reach gut epithelium in places where
the mucus layer is firm and impermeable to bacteria [85,108].
Interactions of A. muciniphila outer membrane proteins with cells of the human immune
system have been studied in vitro [83,109]. These outer membrane proteins are involved in the
health-promoting effects of A. muciniphila towards the intestinal homeostasis and barrier function
(Table 1). The 32 kDa pili-like protein (Amuc_1100), was found to induce IL-1β, IL-6, IL-8, IL-10,
and TNF-α production in human-derived peripheral blood mononuclear cells (PBMCs) [83]. Toll-like
receptor (TLR) 2 was induced by the purified recombinant Amuc_1100 protein. Furthermore, both
A. muciniphila and purified Amuc_1100 enhanced trans-epithelial resistance. Interestingly, treatment
with Amuc_1100 protein (or pasteurized A. muciniphila) lowered body weight and fat mass gain in
HF-diet fed mice, corrected HF-diet-induced higher adipocyte diameter and hypercholesterolemia and
improved glucose tolerance [84]. Furthermore, Amuc_1100 maintained its activity in stimulating TLR2
after pasteurization, as its melting temperature is 70◦C. Thus, Amuc_1100 seems to be responsible for
mediating at least part of the beneficial effects of A. muciniphila. The first clinical trial suggests that
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live or pasteurized A. muciniphila is safe for use for obese humans and it is a promising candidate for
next-generation probiotics [84].
4.3. Faecalibacterium prausnitzii
F. prausnitzii is one of the most abundant bacterial species inhabiting the human intestine,
representing 2–15% of the total bacterial load [110,111]. Taxonomically, F. prausnitzii belongs to
the phylum Firmicutes, class Clostridia, and family Ruminococcaceae with the species currently being
the only characterized representative within the genus [112]. The species itself comprises at least two
distinct phylogroups based on 16S rRNA sequencing [113]. Metabolically, F. prausnitzii is an extremely
oxygen-sensitive anaerobe [112]. The bacterium can use various simple sugars as its energy source,
whereas the utilization of more complex carbohydrates is strain-specific [114]. The nutrients may
be either host- or diet-derived, or they may result from cross-feeding by other gut microbes [114].
The major fermentation products from glucose and acetate by F. prausnitzii are formate, D-lactate,
and butyrate [112].
F. prausnitzii promotes gut health in various ways [114,115]. For instance, it is involved in the
feeding of colonocytes, the maintenance of immune homeostasis, and the strengthening of barrier
function. It has also been noted that the abundance of F. prausnitzii is significantly decreased in
several intestinal disorders, such as Crohn’s disease (CD), UC, and colorectal cancer [116–118],
making it a potential biomarker in the diagnostics of various intestinal disorders. This depletion
may result from changes in the environmental parameters, as the bacterium has been shown to be
sensitive to environmental changes that accompany intestinal disorders [114]. Replenishment of
the diseased gut with F. prausnitzii could improve intestinal health making this bacterium a vital
part of commensal microbiota [114,115]. In healthy human subjects the consumption of prebiotics,
such as inulin (10 g/day) or other dietary fiber (21 g/day), significantly increased the abundance of
F. prausnitzii [119,120]. Thus, the health-promoting action of prebiotics and fiber could be, in part,
mediated by the increase of F. prausnitzii and other beneficial commensals.
In respect to health, the substantial production of butyrate by F. prausnitzii is of special
interest. Butyrate is a major energy source for colonocytes [55] and it also takes part in immune
modulation by inhibiting nuclear factor kappa B (NF-κB) transcription factor activation, upregulating
peroxisome proliferator-activated receptor gamma (PPARγ), and inhibiting IFN-γ, consequently
reducing inflammation (Figure 2) [114]. These anti-inflammatory properties may protect the colon
against inflammation and colorectal cancer. As a member of the intestinal ecosystem, F. prausnitzii is in
constant association with its environment and, therefore, relies on other microbes in order to exhibit
its health-promoting effects. It has been proposed that metabolically complementary F. prausnitzii
and Bacteroides thetaiotaomicron modulate the intestinal mucus barrier by affecting the development of
goblet cells and the production of mucus glycans [121].
It has been shown that F. prausnitzii interacts with the host epithelial cells and attenuates the
inflammatory response. According to Sokol et al., F. prausnitzii affects the release of cytokines
in vitro from PBMCs in a manner that favors the anti-inflammatory cytokine profile (high IL-10/IL-12
ratio) [117]. In the same study, the cell-free culture supernatant of F. prausnitzii was shown to reduce
the secretion of IL-8 by CaCo-2 cells and to abolish NF-κB activation. Interestingly, the latter was
not achieved with butyrate. The experiments on a murine model with acute chemical-induced
inflammation showed that both F. prausnitzii cells and supernatant reduced the severity of acute
colitis and induced increased secretion of anti-inflammatory IL-10 and decreased secretion of
proinflammatory cytokines [117]. Furthermore, F. prausnitzii cells and supernatant were shown to
decrease intestinal permeability by affecting apical junction proteins [122] and enhance the barrier
function in murine model with chemical-induced colitis [123]. In addition to butyrate, F. prausnitzii
produces salicylic acid, which blocks the activation of NF-κB, and, consequently, the production
of IL-8 [124]. Furthermore, F. prausnitzii produces an anti-inflammatory protein called Microbial
Anti-inflammatory Molecule (MAM), whose peptides inhibit the activation of NF-κB in vitro and
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in vivo (Table 1) [86,125]. The anti-inflammatory properties of MAM produced by F. prausnitzii were
also shown to inhibit T helper 1 cells (Th1) and Th17 immune responses in chemically-induced colitis
models in mice [86]. Although it is evident that F. prausnitzii or its components are able to modulate
immune responses, many of the effector molecules still remain uncharacterized, emphasizing the
need for further studies. Since all the F. prausnitzii strains isolated from healthy volunteers showed
promising anti-inflammatory properties in vitro [126], the species is a promising target for therapeutic
purposes. However, the development of therapeutic supplements utilizing strictly anaerobic bacteria,
such as F. prausnitzii, is undoubtedly challenging due to the demand of anaerobic conditions and
large-scale production. Possible solutions would be freeze-drying the microbial cell biomass, followed
by encapsulation or isolating the commensal-derived effector molecules harboring the beneficial
effect [127,128].
4.4. Roseburia intestinalis
R. intestinalis is a Gram-positive, anaerobic, butyrate-producing bacteria originally isolated
from the human feces [129]. It belongs to the phylum Firmicutes and family Lachnospiraceae.
The genus Roseburia includes five characterized species, R. intestinalis, R. hominis, R. inulinivorans,
R. faecis, and R. cecicola [130,131]. The species of genus Roseburia are among the most abundant
butyrate-producing bacteria accounting for 0.9 to 5.0% of the total microbial load [132]. The abundance
of Roseburia has been found to be decreased in many intestinal disorders suggesting the bacterium
has an important role in maintaining the gut homeostasis, e.g., by producing SFCAs [133]. Significant
reduction in the abundance of Roseburia spp. and other butyrate and propionate-producing bacteria
has been observed in patients with UC [101,134]. Similarly, the abundance of R. inulivorans and
other butyrate producers has been shown to be decreased in patients with CD compared to healthy
controls [135]. Geirnaert et al. studied the microbiota profile of CD patients after supplementation of
butyrate-producing bacteria, including R. hominis and R. inulivorans, using an in vitro system [136].
The mix of six butyrate producers increased the level of butyrate in the dysbiosed bacterial
community and improved the epithelial barrier function in an in vitro model, which suggests that
butyrate-producing bacteria may have a therapeutic potential as probiotics.
R. intestinalis has also been shown to exert anti-inflammatory actions in in vivo and in vitro models.
R. intestinalis exhibited an anti-inflammatory pattern regarding cytokines in mono-associated mice
by inducing increased, anti-inflammatory cytokine IL-22 production and decreased the production
of proinflammatory cytokines IFNγ and IL-17 [137]. Similar results were obtained in another study,
which demonstrated the inhibited secretion of IL-17 in vivo and in vitro by R. intestinalis [138]. In the
same study, the bacterium also promoted the differentiation of Treg cells in a colitis mouse model.
Furthermore, R. intestinalis exerted anti-inflammatory action against LPS-triggered inflammation in
enterocytes by promoting the secretion of thymic stromal lymphopoietin (TSLP) and transforming
growth factor beta (TGF-β) [139]. R. intestinalis colonizes the gut epithelium possibly by using its
flagella to penetrate the mucus layer [140]. The flagellin may act as an effector molecule as it has been
shown to induce anti-inflammatory effects by upregulating certain IncRNA (Table 1) [87].
4.5. Eubacterium hallii
Eubacterium hallii is one the major butyrate producers found in the human gut [141]. Quantitatively,
the species represents up to 3% of the total bacteria present in the feces of healthy individuals [110].
As for the taxonomy, this obligate anaerobe belongs to the phylum Firmicutes, class Clostridia, and family
Eubacteriaceae [142]. The amount of Eubacterium spp. have been reported to decrease in patients with
UC and CD as compared to healthy individuals, indicating its value in a healthy, balanced microbial
community [135,143]. With respect to intestinal health, E. hallii could also be involved in detoxification
of the most abundant dietary carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine by
transforming the compound into glycerol-derived conjugate in the colon [144].
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As E. hallii cannot use complex carbohydrates, it relies on simple sugars or metabolic intermediates
as energy sources [145]. The production of butyrate by E. hallii has been shown to result from either
utilization of glucose, or acetate and lactate [146]. In the human gut, where E. hallii is part of complex
nutritional webs, this bacterium is presumably cross-fed by other microbes. Co-culture studies have
revealed cross-feeding interactions between lactobacilli, bifidobacteria, and butyrate-producing colon
bacteria [147,148]. As inulin-type fructans are metabolized into acetate and lactate by lactobacilli
and bifidobacteria, E. hallii and other butyrate-producing bacteria can use the metabolites in the
production of butyrate. The relationship between E. hallii and A. muciniphila is another example of
cross-feeding as these two bacteria exhibit bidirectional syntropy. Belzer et al. [98] has showed that
as A. muciniphila degrades mucin, it releases oligosaccharides and 1,2-propanediol which E. hallii
can use for growth. In turn, E. hallii produces pseudovitamin B12, which A. muciniphila can then
use to produce propionate. Additionally, other mucin-degrading bacteria, such as B. bifidum can
provide mucin-derived monosaccharides to E. hallii, which is then able to utilize lactose, galactose,
and N-acetylglucosamine (GlcNac). The co-culture of these two bacteria has been shown to result in
the production of acetate, butyrate, propionate and formate [147,148]. Recently, E. hallii was shown
to harbor the capability to produce propionate also independently and to stimulate its production in
other microbes [149].
4.6. Bacteroides spp.
Bacteroides species belong to the major phylum Bacteroidetes. The genus Bacteroides contains
the most predominant species of Bacteroidales order in the human intestinal tract [150]. Bacteroides
species are adapted to colonize the harsh environment of the intestine with different mechanisms, such
as oxygen toleration using cytochrome bd oxidase, metabolizing a variety of diet- and host-derived
polysaccharides, and extensive expression of cell surface structures [151]. One of the most abundant
species, Bacteroides fragilis, a Gram-negative obligate anaerobe, exhibits both beneficial and pathogenic
actions for the host [152,153]. The health-promoting properties of the species within this genus have
been recognized relatively recently with B. fragilis being the best studied representative.
B. fragilis produces an immunomodulatory molecule called polysaccharide A (PSA),
which activates T-cell-dependent immune responses involved in the gut homeostasis (Table 1) [154].
The bacterium is capable of niche-specific mucosal colonization in the gut, which is PSA-mediated by
activating Treg cells through TLR2 signaling to suppress Th17 responses and, thus, inducing mucosal
tolerance [155]. Specifically, PSA has been shown to protect from Helicobacter hepaticus induced colitis
in mice suggesting it has immunomodulatory capacity and is a potential therapeutic mechanism to
the host [88]. Moreover, this symbiotic surface factor has been shown to decrease IL-1β-induced IL-8
cytokine levels in human fetal enterocytes, necrotizing enterocolitis enterocytes, and in fetal mouse
small intestine through the stimulation of TLR2 and TLR4 receptors [156]. In the DSS-induced colitis
mouse model, B. fragilis inhibits the expression of proinflammatory cytokines IL-6 and TNF-α and
enhances the anti-inflammatory IL-10 expression, and thereby ameliorates colitis symptoms [88,157].
In another mouse model, B. fragilis enforces epithelial barrier by correcting intestinal permeability,
tight-junction alterations and cytokine expression [158]. In addition, B. fragilis affects the host immune
system by enhancing the phagocytic function of macrophages and polarizing them into the M1
phenotype, which promotes Th1 response [159].
B. fragilis communicates with the host immune system, e.g., via its PSA, which is delivered
to dendritic cells packed in outer membrane vesicles (OMVs) released from the bacterial surface
(Table 1) [89]. Secretion of these signaling molecules enables Bacteroides spp. to interact with the
intestinal epithelium, which would be otherwise inaccessible due to the thick mucus layer [160].
Bacteroides vulgatus, which has been shown to protect against E. coli -induced colitis in monocolonized
mice, and also produces OMVs and regulates immune responses in the host [160,161]. In addition
to B. fragilis, other less studied Bacteroides spp. are also capable of producing multiple capsular
polysaccharides making their surface structures more diverse [162]. Different Bacteroides spp.
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isolated from fecal microbiota transplantation (FMT)-donor were capable of attenuating LPS-induced
inflammation in vitro, which indicates that they may exert anti-inflammatory action in the intestine [163].
However, the attenuation capacity is not adhesion-dependent suggesting the bacteria may secrete
effector molecules responsible for the interaction with the enterocytes. The currently used probiotics
on the market may not colonize the intestinal tract in the long-term. Many of the probiotic strains
have been isolated originally from other niches than the human gut, which could explain their poor
colonization capacity. For this reason, these next-generation probiotics are of interest as they could
possibly colonize the gut more efficiently, being adapted to the intestinal conditions. In fact, results from
FMT-studies suggest long-term colonization of commensal donor species, including Bacteroides spp.,
in the recipients [164,165].
5. Conclusions
Certain intestinal bacteria, like those discussed above, reinforce the host epithelium and give
cross-tolerance to LPS, which counteracts or decreases the toxic effects of LPS in dysbiosis. Furthermore,
these commensal gut colonizers produce immunoregulatory effects via secreted metabolites, such
as SCFAs, especially butyrate. Roseburia, Faecalibacterium, and E. hallii-related bacteria are the most
abundant butyrate-producers in the human gut [132]. Moreover, cross-feeding chains have been
established between bifidobacteria, F. prausnitzii and R. intestinalis, which enhance the butyrate
production in the colon. Additionally, A. muciniphila takes part in the cross-feeding by degrading
complex mucin glycoproteins to oligosaccharides, which E. hallii and other butyrate producers, in turn,
are able to use for growth and, thus, the production of butyrate. The importance of butyrate producers
to gut health is well established, since these bacteria are significantly reduced in many intestinal
diseases. Bacteroides species, on the other hand, exert different mechanisms to enhance the gut
homeostasis, e.g., secreting immunomodulatory effector molecules. The B. fragilis-produced PSA
molecule is an exciting discovery in this field. The mechanisms of action of the potential next-generation
probiotics at the molecular level are still largely unknown, but the knowledge is increasing rapidly.
Dietary changes and the use of antibiotics associated with intestinal diseases also modulate the
microbiota composition, which plays a part in the depletion of essential health-promoting commensals
in the colon and, thus, contributes to unbalanced microbiota composition. The most drastic example
of disturbed microbial ecosystem and function by antibiotics and, on the other hand, its restoration
by bacteriotherapeutic supplementation, is recurrent Clostridium difficile infection and its treatment
with fecal microbiota transplantation [164]. Considering the beneficial effects of the commensal species
in fortifying intestinal barrier function and immunoregulation discussed above, it seems justified to
consider strategies to promote their presence and activity in the human gut. This could be achieved
by de novo introduction of the species into the gut in the form of probiotic or bacteriotherapeutic
preparations or by stimulating the growth of the species in the gut by dietary means, or the combination
of these two [128,166]. As a promising example, the treatment with A. muciniphila has been shown
to counteract high fat diet -induced complications and gut barrier dysfunction in mice and the
bacterium is tested safe for humans [84,104,105]. The dietary approaches include adequate dosages
of fiber and prebiotics, whose beneficial effects are transmitted to the host particularly through
bacterial fermentation and the health-promoting action of commensals that are stimulated by these
compounds [167]. Interestingly, the microbiota composition and presence of certain key commensal
species seem to affect the individual’s fiber fermentability capacity, as was discovered in a feeding study
where individuals lacking Ruminococcus bromii had reduced fermentability (20–30% compared to 100%)
of resistant starch [168]. Within prebiotics, inulin-type fructans and oligosaccharides mimicking HMOs
have already shown promising efficacy in modulating the microbiota composition and metabolism,
in which cross-feeding has a central role at the gut ecosystem level.
In the future, increased knowledge on the cross-feeding chains within microbiota combined
with the affordable profiling of individual’s microbiota will open exciting and efficient possibilities
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in personalized nutrition to modulate the composition and action of gut microbiota in the
desired direction.
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